[CAS NO. 154-17-6] 2-Deoxy-D-glucose

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [154-17-6]

Catelog

HY-13966

Brand

MCE

CAS

154-17-6

DESCRIPTION [154-17-6]

Overview

MDL	MFCD00151328
Molecular Weight	164.16
Molecular Formula	C6H12O5
SMILES	OC1O[C@@H]([C@@H](O)[C@H](O)C1)CO

For research use only. We do not sell to patients.

83 Publications Citing Use of MCE

Summary

2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase ^[1] .

IC50 & Target

HSV-1

In Vitro

2-Deoxy-D-glucose (2-DG, 4, 8, or 16 mM) significantly reduces the level of ATP in MCF-7 cells in a dose- and time-dependent manner that paralleles the effects of 2-DG on cell growth. The levels of phosphorylated Akt are significantly decreased, whereas the levels of phosphorylated AMPK and Sirt-1 are significantly increased in MCF-7 cells exposed to 2-Deoxy-D-glucose at 4, 8, or 16 mM for 1, 3, or 5 days in a dose- and time-dependent manner ^[1] . 2-DG treatment increases the levels of pentose phosphate pathway (PPP) metabolites and augments the generation of NADPH by glucose-6-phosphate dehydrogenase. An increase in NADPH and upregulation of glutathione synthetase expression resultes in the increase in the reduced form of glutathione by 2-DG in NB4 cells ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

2-Deoxy-D-glucose (0.03%, w/w) causes a 7% decrease in final weight that is statistically significant, and delayes the appearance of palpable mammary carcinomas ^[1] . 2-Deoxy-D-glucose (3 mmol/kg, i.v.) is decreased in a dose-dependent manner in rat muscle ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00247403	University of Iowa	Intracranial Neoplasms\|Neoplasm Metastasis	October 2005	Phase 1
NCT00096707	Threshold Pharmaceuticals	Lung Cancer\|Breast Cancer\|Pancreatic Cancer\|Head and Neck Cancer\|Gastric Cancer	February 2004	Phase 1
NCT05605301	University of Virginia\|Epilepsy Foundation\|University of Wisconsin, Madison	Epilepsy; Seizure	September 2, 2022	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : ≥ 24 mg/mL ( 146.20 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.0916 mL	30.4581 mL	60.9162 mL
5 mM	1.2183 mL	6.0916 mL	12.1832 mL
10 mM	0.6092 mL	3.0458 mL	6.0916 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 130 mg/mL (791.91 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

D-arabino-Hexose, 2-deoxy-

2-Deoxy-D-arabino-hexose

D-Glucose, 2-deoxy-

2-Deoxyglucose

Ba 2758

2-Deoxy-D-glucose

2-Desoxy-D-glucose

2-Deoxy-D-mannose

NSC 15193

2 DG